bioAffinity Technologies, Inc. has closed its previously announced public offering of securities, raising aggregate gross proceeds of $3.2 million before deducting agent fees and expenses. The offering consisted of 4,000,000 shares of common stock at a purchase price of $0.80 per share, with pre-funded warrants available in lieu thereof at $0.793 per warrant. Each pre-funded warrant is exercisable for one share of common stock, is immediately exercisable, and will expire upon full exercise.

WallachBeth Capital, LLC acted as the sole placement agent for the offering. The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-296764), which was declared effective by the Securities and Exchange Commission (SEC).

Offering Details

bioAffinity Technologies focuses on the development of noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases. The company's first product, CyPath® Lung, is marketed as a Laboratory Developed Test (LDT) by its subsidiary, Precision Pathology Laboratory Services.

bioAffinity Technologies, Inc., alongside Philips and 4DMedical, announced a webinar on July 21, 2026, to showcase emerging approaches for lung health screening and early detection in U.S. veterans. The program aims to address challenges in managing lung disease, particularly for veterans at increased risk due to toxic exposures recognized under the PACT Act. By integrating mobile CT screening, noninvasive CyPath Lung testing, and comprehensive functional lung imaging, the initiative seeks to reduce costs while improving access and clinical outcomes.

The webinar will feature clinical perspectives on lung cancer risk among veterans, the evolving role of imaging, and opportunities to enhance patient access to screening and follow-up care. Speakers will discuss strategies for implementing comprehensive lung health programs, with a focus on earlier detection and improved clinical decision-making. The event is intended for healthcare professionals in pulmonary medicine, oncology, radiology, primary care, and veteran health services.

Key Participants and Topics

The panel includes experts from bioAffinity Technologies, Philips, and 4DMedical, moderated by Rashi Romanoff, Chief Executive Officer of the National Association of Veterans' Research and Education Foundations (NAVREF). NAVREF supports the research and education mission of the Department of Veterans Affairs by fostering public-private partnerships and accelerating healthcare solutions for veterans.

Diagnostic Technologies Highlighted

The webinar will explore CyPath Lung, a noninvasive test developed by bioAffinity Technologies for early-stage lung cancer detection. The test uses advanced flow cytometry and proprietary artificial intelligence to identify cell populations in patient sputum indicating malignancy. In a published clinical trial, CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, and 99% negative predictive value (NPV) in detecting lung cancer in high-risk patients with small indeterminate lung nodules.

Philips will contribute insights on mobile CT screening and technology-enabled care models, while 4DMedical will present its proprietary platform for noninvasive visualization of lung motion and airflow. These technologies aim to enable earlier detection of respiratory diseases and improved patient management. The high NPV of CyPath Lung provides physicians with greater confidence in negative results, potentially sparing patients from unnecessary invasive procedures.

Event Details

The webinar is scheduled for July 21, 2026, at 6 p.m. ET/5:00 p.m. CT. Veterans experience a higher incidence of lung cancer than the general population, underscoring the importance of timely screening and diagnostic evaluation. The program will provide healthcare professionals with insights into current clinical practices and emerging technologies to support improved outcomes for at-risk patients. Registration is available online for interested participants.